The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study

Authors :: Terry M. Jones
M. Lee
Robert C. Higham
Charlotte Merritt
Scott Guenthner
Melinda Gooderham
Matthew J. Zirwas
Neal Bhatia
Meg Elias
Michael Droege
Etienne Saint-Cyr Proulx
Zoe Draelos
Robert Bissonnette
Laura K. Ferris
David R. Berk
Howard Welgus
Robert A. Koppel
Lynn Navale
Leon H Kircik
Steven Kempers
Source :: SKIN The Journal of Cutaneous Medicine. 4:s93
Publication Year :: 2020
Publisher :: National Society for Cutaneous Medicine, 2020.
Abstract: not available.

Subjects :: medicine.medical_specialty
business.industry
Proof of concept
Medicine
Atopic dermatitis
Phosphodiesterase inhibitor
business
medicine.disease
Dermatology
Roflumilast
medicine.drug

Full Text Access

Tools